Overview of Dr. Fitzpatrick
Dr. Kelly Fitzpatrick is a hematologist-oncologist with Regional Cancer Care Associates in NJ, primarily as part of the HOPE tower Leukemia and BMT team at Hackensack Meridian Jersey Shore University Medical Center but also affiliated with the John Theurer Cancer Center in Hackensack since Nov 2021. Previously, she worked as an academic hematologist at MedStar Washington Hospital Center in DC.
Education & Training
MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 2009 - 2012
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 2006 - 2009
Georgetown University School of MedicineClass of 2006
Certifications & Licensure
NJ State Medical License 2021 - 2025
DC State Medical License 2006 - 2024
MD State Medical License 2012 - 2022
VA State Medical License 2006 - 2022
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2012, 2014
Publications & Presentations
PubMed
- 14 citations
Efficacy and Safety of Direct-Acting Oral Anticoagulants (DOACs) in the Overweight and Obese.
Kimberley Doucette, Hira Latif, Anusha Vakiti, Eshetu Tefera, Bhavisha A Patel, Kelly W. Fitzpatrick> ;Advances in Hematology. 2020 May 23 - 15 citations
Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab.
Anusha Vakiti, Daulath Singh, Ravi Pilla, Muhamad Alhaj-Moustafa, Kelly W. Fitzpatrick> ;Journal of Oncology Pharmacy Practice. 2019 Jun 1 - 9 citations
DA-EPOCH-R for post-transplant lymphoproliferative disorders
Christin B. DeStefano, Vera Malkovska, Hind Rafei, Aarthi Shenoy, Kelly W. Fitzpatrick, Anita Aggarwal, Joseph P. Catlett> ;European Journal of Haematology. 2017 Sep 1 - Join now to see all
Journal Articles
90Y-Epratuzumab, a Humanized Yttrium-Radiolabeled Anti-CD22mAb for the Potential Treatment of Non-Hodgkin's Lymphoma.
KW Fitzpatrick, BD Cheson, Thomas Reuters Drug Profiles, 2/20/2012
